semaglutide oral medication ACC 2025: Reduces Cardiovascular Events by 14% at 4 Years RYBELSUS® (semaglutide) tablets 7 mg

Description TIRZEPATIDE INFOR MATION (GLP-1 + GIP) BENEFITS Decreased appetite and cravings Weight loss Clinical trials showed 15% to 30% weight loss depending on doses Each individual loses weight at their own rate Compounded formulas are compounded with medication to help alleviate side effects of nausea Injections are once weekly You can repeat program as many times as you wish COMMON SIDE EFFECTS Nausea Constipation Upset stomach Indigestion RISK OF THYROID C-CELL TUMORS If you or any family member has been diagnosed with Multiple Endocrine Neoplasia Syndrome Type 2 or medullary thyroid cancer you should not take Tirzepatide INFORMATION Tirzepatide is a combination glucagon-like peptide 1 (GLP-1) receptor AND glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that acts on areas of brain that regulate food intake and appetite

The rate of the population that is considered obese or overweight continues to climb, making more effective means of treating obesity incredibly important to help lower the risk of associated health conditions in the general population

Cooperate with CBP officers if they have questions

Patients should also ensure proper skin hygiene before injections, cleansing the area with an alcohol wipe and allowing it to dry completely before administering the medication

Weeks 17 through 20: fourth escalation Dose: 12.5mg once weekly Not all patients reach this dose